As part of its long-term plans in Ireland, MSD has agreed to acquire the WuXi Vaccines manufacturing facility located in Dundalk, Co Louth.

The acquisition signifies an investment of over €500m, which comes on the back of the company’s recent announcement of a €1bn investment across its sites in Carlow and Dunboyne, Co Meath, just last year. 

MSD and WuXi Vaccines will now begin an official handover process which aims to be completed in the first half of 2025. 
 
MSD Ireland is looking ahead to significant growth across its network, and, including this acquisition, is planning to add about 1,000 jobs over coming years across its eight locations in counties Carlow, Cork, Dublin, Louth, Meath and Tipperary. 
 
The newly acquired Dundalk site is a 15,520-square-metre, three-storey vaccine manufacturing facility featuring drug substance manufacturing, drug product manufacturing, and quality control labs for the supply of vaccine products for the global market, employing about 200 professionals on site. 

Successful collaboration 

This acquisition by MSD is a testament to a successful collaboration and long-standing partnership between both companies over recent years, which saw MSD and WuXi Vaccines collaborating on site in Dundalk since 2019. 
 
An Taoiseach Simon Harris said: “Today’s announcement is highly welcome news and is a tremendous vote of confidence in the people of Dundalk and Co. Louth. MSD is a long-standing partner to Ireland and has shown an unwavering commitment both to the country and to its drive to innovate.

"The acquisition of the Dundalk facility, along with the company’s plans to add 150 additional jobs to it, as part of an overall increase of 1,000 positions across its Irish operations in the coming years will play an important role in its development and delivery of innovative products that will improve the lives of millions of people around the world.”
 
Michael Lohan, CEO of IDA Ireland, said: “This acquisition and accompanying 150 new roles announcement by MSD Ireland is a huge testament to Ireland’s position as a global leader in the pharmaceutical value chain, continuously attracting strategically  innovative investments to our shores.

"Our partnership with MSD Ireland spans nearly 50 years, and it’s exciting to see the company continue to both deepen and broaden its roots all across the country, expanding to its new location in Dundalk.”
 
Sanat Chattopadhyay, executive vice president and president of MSD’s Manufacturing Division, said: “MSD’s manufacturing footprint in Ireland is unparalleled, and I am proud to oversee its continuous expansion, always looking to advance the future of health through innovation and acceleration in the service of people and patients around the world.

"The acquisition of this WuXi Vaccines site in Dundalk will give us the opportunity to do just that: deliver for people and patients faster, looking at the health challenges of today and tomorrow.”
 
Samantha Humphreys, managing director of MSD Ireland Human Health, said: “Our company’s continued ambition to expand MSD’s Irish footprint is a testament to the unique ecosystem around us, and in particular speaks to the passion, commitment and talent of our existing 3,000-strong workforce and what they have been able to accomplish for our global network – from MSD Ireland to the world.

'Adding new capabilities'

"I am very proud to be part of this exciting new chapter as we continue to expand, adding new capabilities and challenging ourselves to look at the health requirements of the future.”
 
MSD Ireland is one of the country’s leading healthcare companies, having first established in Ireland in 1976. At present, the company has a dynamic and diverse team of more than 3,000 employees currently working across seven locations in counties Carlow, Cork, Dublin, Meath and Tipperary.

Working across all stages of pharmaceutical development, the company’s Irish network is focused on leveraging innovation to respond to the health threats of today and tomorrow, working at the forefront of science and technology to advance manufacturing excellence and future focused R&D. 
 
The Dundalk site will become part of the company’s existing network of five cutting-edge, large-scale pharma manufacturing, research, and development sites across the country – MSD Ballydine, MSD Brinny, MSD Carlow, MSD Dunboyne and MSD Biotech, Dublin – and substantial animal health and human health operations across two locations in Dublin.